Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

GM Crops - The Elephant In The Room? - Sustainable Agriculture Still Low Down On EU Climate Change Agenda
GM crops can and already do play an important role in reducing the negative environmental impacts of agriculture and feeding a growing population in a worsening climate, reveals a report published today by EuropaBio[i]. Furthermore, this contribution will only increase as their cultivation becomes even more widely adopted around the world. Nevertheless, this fact continues to be ignored by many EU regulators, as is evidenced by its repeated non-appearance on DG Environment"s Green Week agenda.
generic viagra online
Arrayit Corporation Addresses Flu Pandemic
Arrayit Corporation (OTCBB: ARYC), a leading manufacturer of products and services for disease prevention, treatment and cure, announced that its microarray-based diagnostic test, patented under the trade name Variation Identification Platform (VIP), is ready for manufacture and distribution. A breakthrough screening test using VIP will allow clinicians and researchers to test and detect the H1N1 swine flu virus in population wide studies.
News of the day
Medtronic Annual Meeting Date Scheduled For August 27, 2009
The board of directors of Medtronic, Inc. (NYSE: MDT), announced that the company"s annual meeting of shareholders will be held at 10:30 a.m., Central Daylight Time, on Thursday, August 27, 2009 at Medtronic World Headquarters, located at 710 Medtronic Parkway, Minneapolis, Minnesota. Shareholders of record at the close of business on June 29, 2009, will be eligible to vote at the meeting.
Cardiovascular

New Clinical Study On Type 2 Diabetes Begins Enrollment At New York Hospital Queens

Diabetes affects nearly 24 million people in the United States. The most widespread form is type 2 diabetes, accounting for about 90 to 95 percent of all diagnosed cases of diabetes, according to the American Diabetes Association (ADA). The research team at New York Hospital Queens is offering the community a chance to participate in a new type 2 diabetes study. The study, called TINSAL-T2D (Targeting Inflammation using Salsalate in Type 2 Diabetes), looks at the safety and effectiveness of an investigational medication (similar to aspirin) in the treatment of type 2 diabetes. The study medication has been approved by the U.S. Food and Drug Administration to treat arthritis, but it has not yet been approved for diabetes. To be eligible for this study, participants must have type 2 diabetes, be between 18 and 75 years old, and be on a stable dose of oral anti-diabetic medication and the diabetes is still not well controlled. The study includes 12 visits to the Lang Research Center over approximately one year. Qualified participants will receive a physical exam and laboratory tests at no cost. Participants will be compensated for their time and effort. Nationally lauded endocrinologist, Daniel Lorber, M.D., associate director, Eugene and Theresa Lang Research Center for Research and Education at New York Hospital Queens, is the principal investigator of the clinical trial. Last month, Dr. Lorber received the ADA"s "Outstanding Physician Clinician Award" for his contributions to the ongoing fight against diabetes. A clinical trial is a scientific study that evaluates the safety and effectiveness of medical treatments, drugs or devices. These studies are required by the U.S. Food and Drug Administration for manufacturers to earn approval for new products and new uses for existing products. New York Hospital Queens is a member of the NewYork-Presbyterian Healthcare System and is an affiliate of the Weill Medical College of Cornell University. American Diabetes Association


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009